MDM4 is a key therapeutic target in cutaneous melanoma
- 22 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 18 (8), 1239-1247
- https://doi.org/10.1038/nm.2863
Abstract
Although loss-of-function p53 alterations are widespread in many tumors, melanomas typically do not harbor TP53 mutations. This report uncovers upregulation of MDM4 as a frequent trait of melanomas that contributes to tumorigenesis by inactivating p53 signaling. MDM4 is required for growth and survival of melanoma cell lines, and compounds that can target MDM4 are effective against melanoma in vivo and against tumors resistant to BRAF-targeted therapy in vitro. The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in melanoma—a highly chemotherapy-resistant disease—TP53 mutations are rare, raising the possibility that this cancer uses alternative ways to overcome p53-mediated tumor suppression. Here we show that Mdm4 p53 binding protein homolog (MDM4), a negative regulator of p53, is upregulated in a substantial proportion (∼65%) of stage I–IV human melanomas and that melanocyte-specific Mdm4 overexpression enhanced tumorigenesis in a mouse model of melanoma induced by the oncogene Nras. MDM4 promotes the survival of human metastatic melanoma by antagonizing p53 proapoptotic function. Notably, inhibition of the MDM4-p53 interaction restored p53 function in melanoma cells, resulting in increased sensitivity to cytotoxic chemotherapy and to inhibitors of the BRAF (V600E) oncogene. Our results identify MDM4 as a key determinant of impaired p53 function in human melanoma and designate MDM4 as a promising target for antimelanoma combination therapy.Keywords
This publication has 53 references indexed in Scilit:
- Regulating the p53 pathway: in vitro hypotheses, in vivo veritasNature Reviews Cancer, 2006
- Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Cancer Research, 2006
- Amplification of CDK4 and MDM2 in malignant melanomaGenes, Chromosomes and Cancer, 2006
- Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61K on an INK4a-Deficient BackgroundCancer Research, 2005
- Mdmx as an essential regulator of p53 activityBiochemical and Biophysical Research Communications, 2005
- The role of B-RAF in melanomaCancer and Metastasis Reviews, 2005
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.1999
- Tumor spectrum analysis in p53-mutant miceCurrent Biology, 1994